These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 31207293

  • 21. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X, Liu D.
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [Abstract] [Full Text] [Related]

  • 22. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.
    Leon Rodriguez E, Rivera Franco MM, Perez Alvarez SI.
    Ann Hematol; 2017 Sep; 96(9):1525-1531. PubMed ID: 28691152
    [Abstract] [Full Text] [Related]

  • 23. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
    Swaminathan VV, Uppuluri R, Patel S, Ravichandran N, Ramanan KM, Vaidhyanathan L, Ramakrishnan B, Jayakumar I, Raj R.
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
    [Abstract] [Full Text] [Related]

  • 24. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S, Gross TG, Rangarajan H, Baker KS, Sturm M, Rhodes M.
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [Abstract] [Full Text] [Related]

  • 25. Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide.
    Fouzia NA, Edison ES, Lakshmi KM, Korula A, Velayudhan SR, Balasubramanian P, Abraham A, Viswabandya A, George B, Mathews V, Srivastava A.
    Bone Marrow Transplant; 2018 Feb; 53(2):169-174. PubMed ID: 29035392
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia--a single-center experience.
    Wang H, Wang Z, Zheng X, Ding L, Zhu L, Yan H, Guo Z.
    Cytotherapy; 2013 Sep; 15(9):1118-25. PubMed ID: 23806238
    [Abstract] [Full Text] [Related]

  • 29. [Comparison of curative efficacy after G-CSF-mobilized sibling HLA-matched peripheral blood hematopoietic stem cell transplantation versus that combined with BMT for patients with hematologic malignancies in a single center].
    Ren FP, Liu HL, Sun ZM, Geng LQ, Wang XB, Ding KY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):404-9. PubMed ID: 21518497
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A.
    J Hematol Oncol; 2017 Jan 24; 10(1):31. PubMed ID: 28118857
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation.
    Ji SQ, Chen HR, Xun CQ, Wang HX, Pan SP, Xiao MH.
    Clin Transplant; 2001 Oct 24; 15(5):317-23. PubMed ID: 11678957
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies.
    Cai X, Wei J, He Y, Yang D, Jiang E, Huang Y, Han M, Feng S.
    Int J Clin Pharm; 2015 Feb 24; 37(1):44-52. PubMed ID: 25432692
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Feb 24; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.